FindTrial
Sign In

Study on the Efficacy of Saccharomyces boulardii Powder as an Adjuvant to HD Dual Therapy for H. pylori Eradication and Its Failure Mechanisms

Study on the Efficacy of Saccharomyces boulardii Powder as an Adjuvant to HD Dual Therapy for H. pylori Eradication and Its Failure Mechanisms

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600128447
Enrollment
Unknown
Registered
2026-07-21
Start date
2026-03-15
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori

Interventions

Trial group:Saccharomyces boulardii powder 500 mg bid (after meals), Amoxicillin 1000 mg tid (after meals), Vonoprazan 20 mg bid (before meals), course of treatment 14 days.
Control group:Amoxicillin and Vonorax (dose and usage as above), treatment course 14 days.

Sponsors

Guizhou Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: A total of 200 newly treated Hp-infected patients were included, aged 18-70 years, of all genders, and diagnosed with Hp infection by urea breath test (UBT).

Exclusion criteria

Exclusion criteria: 1. History of previous H. pylori eradication therapy; 2. Severe liver and kidney dysfunction (ALT/AST > 2×ULN or Cr > 1.5×ULN); 3. Digestive tract ulcer bleeding or gastric cancer; 4. Pregnancy or breastfeeding; 5. History of drug allergy; 6. Long-term use of NSAIDs or glucocorticoids.

Design outcomes

Primary

MeasureTime frame
Hp eradication rate;—

Secondary

MeasureTime frame
Medication adherence;—

Countries

China

Contacts

Public ContactWang Yuan

Guizhou Second People's Hospital

987972154@qq.com+86 186 4531 6402

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026